GABELLI FUNDS LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
GABELLI FUNDS LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2021$2,857,000
-6.8%
3,000,0000.0%0.02%
-14.3%
Q1 2021$3,067,000
+8.2%
3,000,0000.0%0.02%
+5.0%
Q4 2020$2,835,000
+7.1%
3,000,0000.0%0.02%
-4.8%
Q3 2020$2,648,000
-9.2%
3,000,0000.0%0.02%
-12.5%
Q2 2020$2,915,000
-0.4%
3,000,0000.0%0.02%
-7.7%
Q1 2020$2,927,000
+42.4%
3,000,000
+50.0%
0.03%
+100.0%
Q4 2019$2,055,000
+11.0%
2,000,0000.0%0.01%
+8.3%
Q3 2019$1,851,000
+6.7%
2,000,0000.0%0.01%
+9.1%
Q2 2019$1,735,000
-10.4%
2,000,0000.0%0.01%
-8.3%
Q1 2019$1,937,000
-5.9%
2,000,0000.0%0.01%
-14.3%
Q4 2018$2,058,000
-12.6%
2,000,0000.0%0.01%0.0%
Q3 2018$2,356,000
+18.9%
2,000,0000.0%0.01%
+16.7%
Q2 2018$1,982,000
-2.1%
2,000,0000.0%0.01%0.0%
Q1 2018$2,024,000
-7.3%
2,000,0000.0%0.01%
-7.7%
Q4 2017$2,184,000
-10.8%
2,000,0000.0%0.01%
-7.1%
Q3 2017$2,449,000
-9.3%
2,000,0000.0%0.01%
-12.5%
Q2 2017$2,699,000
+7.0%
2,000,0000.0%0.02%
+6.7%
Q1 2017$2,523,000
+10.9%
2,000,0000.0%0.02%
+15.4%
Q4 2016$2,274,0002,000,0000.01%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
LINDEN ADVISORS LP 71,957,000$88,374,0003.14%
Context Capital Management, LLC 3,500,000$4,288,0002.87%
Mohican Financial Management, LLC 1,000,000$1,250,0002.40%
Verition Fund Management LLC 8,000,000$9,835,0000.79%
ZAZOVE ASSOCIATES LLC 8,170,000$10,024,0000.51%
Baupost Group 30,000,000$37,125,0000.46%
WOLVERINE ASSET MANAGEMENT LLC 24,020,000$29,431,0000.33%
SSI INVESTMENT MANAGEMENT LLC 3,007,000$3,683,0000.31%
CSS LLC/IL 2,900,000$3,556,0000.17%
Rock Springs Capital Management LP 1,500,000$1,844,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders